Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Cancer Cachexia
Interventions
DRUG

RC-1291 HCl

DRUG

Placebo

Trial Locations (19)

20817

Center for Cancer and Blood Disorders, Bethesda

29210

South Carolina Oncology Associates, Columbia

29406

Charleston Cancer Center, Charleston

29926

South Carolina Cancer Specialists, Hilton Head Island

32901

Melbourne Internal Medicine Associates, Melbourne

Osler Medical, Inc./ Osler Clinical Research, Melbourne

33511

PAB Clinical Research, Brandon

33607

Bay Area Oncology, Tampa

43235

Hematology Oncology Consultants, Inc., Columbus

77555

University of Texas Medical Texas, Galveston

85304

Palo Verde Hematology Oncology Ltd., Glendale

90057

Kenmar Clinical Research, Los Angeles

Kenmar Research Institute, Los Angeles

90403

Sant Chawla, Inc., Santa Monica

92024

Pacific Oncology & Hematology Associates, Encinitas

Pacific Oncology and Hematology Associates, Encinitas

93309

Comprehensive Blood & Cancer Center, Bakersfield

93710

Advanced Medical Research Institute, Fresno

98405

Multicare Health System, Tacoma

All Listed Sponsors
lead

Helsinn Therapeutics (U.S.), Inc

INDUSTRY

NCT00267358 - Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia. | Biotech Hunter | Biotech Hunter